Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate in treatment-resistant inflammatory neuropathies.

T Umapathi1, R Hughes

  • 1Guy's, King's and St Thomas' School of Medicine, London, UK. tumapathi@yahoo.com

European Journal of Neurology
|November 28, 2002
PubMed
Summary

Mycophenolate did not benefit patients with chronic inflammatory demyelinating polyradiculoneuropathy or multifocal motor neuropathy. This immunomodulatory drug did not reduce other immunosuppressants and caused side effects in two patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the impact of anti-PD-1/PD-L1 inhibitors on cancer care health and budget in Greece.

Journal of cancer policy·2025
Same author

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

Evidence of early coronary atherosclerotic plaque in hidradenitis suppurativa compared to the background population is indicative of myocardial infarction risk.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

'Who are you and what do you do?' Using name and role stickers to improve communication and teamwork in intensive care during the COVID-19 pandemic.

Journal of the Intensive Care Society·2023
Same author

Systemic immune inflammation index is a marker of cardiovascular risk and not just disease severity in hidradenitis suppurativa.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Next Level Health: a holistic health and wellbeing program to empower New Zealand women.

Health promotion international·2022

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Mycophenolate is an immunomodulatory drug with growing interest for neuromuscular diseases.
  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) are debilitating conditions.
  • Treatment resistance is a significant challenge in managing these neuropathies.

Purpose of the Study:

  • To evaluate the efficacy of mycophenolate in patients with treatment-resistant CIDP or MMN.
  • To assess the impact of mycophenolate on corticosteroid and other immunosuppressive agent dosages.
  • To document any side effects associated with mycophenolate treatment in this patient cohort.

Main Methods:

  • A case series of five consecutive patients with treatment-resistant CIDP or MMN was reviewed.

Related Experiment Videos

  • Patients received mycophenolate for their respective neuromuscular conditions.
  • Clinical outcomes, changes in medication dosages, and adverse events were recorded.

    • Main Results:

    • None of the five patients demonstrated clinically significant benefit from mycophenolate treatment.
    • Mycophenolate did not lead to a reduction in corticosteroid or other immunosuppressive agent doses in any patient.
    • Two patients discontinued mycophenolate due to bothersome, though not serious, side effects.

    Conclusions:

    • Mycophenolate appears ineffective for treatment-resistant CIDP and MMN based on this small case series.
    • The drug did not facilitate steroid-sparing or reduction of other immunosuppressants.
    • Further investigation into mycophenolate's role in these specific neuropathies is warranted, considering potential side effects.